244 related articles for article (PubMed ID: 27753182)
1. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
Gilbert DC; Duong T; Kynaston HG; Alhasso AA; Cafferty FH; Rosen SD; Kanaga-Sundaram S; Dixit S; Laniado M; Madaan S; Collins G; Pope A; Welland A; Nankivell M; Wassersug R; Parmar MK; Langley RE; Abel PD
BJU Int; 2017 May; 119(5):667-675. PubMed ID: 27753182
[TBL] [Abstract][Full Text] [Related]
2. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Langley RE; Gilbert DC; Duong T; Clarke NW; Nankivell M; Rosen SD; Mangar S; Macnair A; Sundaram SK; Laniado ME; Dixit S; Madaan S; Manetta C; Pope A; Scrase CD; Mckay S; Muazzam IA; Collins GN; Worlding J; Williams ST; Paez E; Robinson A; McFarlane J; Deighan JV; Marshall J; Forcat S; Weiss M; Kockelbergh R; Alhasso A; Kynaston H; Parmar M
Lancet; 2021 Feb; 397(10274):581-591. PubMed ID: 33581820
[TBL] [Abstract][Full Text] [Related]
3. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Langley RE; Kynaston HG; Alhasso AA; Duong T; Paez EM; Jovic G; Scrase CD; Robertson A; Cafferty F; Welland A; Carpenter R; Honeyfield L; Abel RL; Stone M; Parmar MK; Abel PD
Eur Urol; 2016 Jun; 69(6):1016-25. PubMed ID: 26707868
[TBL] [Abstract][Full Text] [Related]
4. A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.
Gilbert DC; Nankivell M; Rush H; Clarke NW; Mangar S; Al-Hasso A; Rosen S; Kockelbergh R; Sundaram SK; Dixit S; Laniado M; McPhail N; Shaheen A; Brown S; Gale J; Deighan J; Marshall J; Duong T; Macnair A; Griffiths A; Amos CL; Sydes MR; James ND; Parmar MKB; Langley RE
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e11-e19. PubMed ID: 37973477
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Langley RE; Cafferty FH; Alhasso AA; Rosen SD; Sundaram SK; Freeman SC; Pollock P; Jinks RC; Godsland IF; Kockelbergh R; Clarke NW; Kynaston HG; Parmar MK; Abel PD
Lancet Oncol; 2013 Apr; 14(4):306-16. PubMed ID: 23465742
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
8. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
9. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
10. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
11. Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial.
Organ M; Wood L; Wilke D; Skedgel C; Cheng T; North S; Thompson K; Winch S; Rendon R
Am J Clin Oncol; 2013 Dec; 36(6):601-5. PubMed ID: 22868247
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
[TBL] [Abstract][Full Text] [Related]
13. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
14. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.
Langley RE; Godsland IF; Kynaston H; Clarke NW; Rosen SD; Morgan RC; Pollock P; Kockelbergh R; Lalani el-N; Dearnaley D; Parmar M; Abel PD
BJU Int; 2008 Aug; 102(4):442-5. PubMed ID: 18422771
[TBL] [Abstract][Full Text] [Related]
15. [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
Eisenhardt A; Schneider T; Scheithe K; Colling C; Heidenreich A;
Urologe A; 2016 Feb; 55(2):176-83. PubMed ID: 26518305
[TBL] [Abstract][Full Text] [Related]
16. Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial.
Russell N; Hoermann R; Cheung AS; Zajac JD; Grossmann M
Eur J Endocrinol; 2022 Nov; 187(5):617-627. PubMed ID: 36806623
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Arai Y; Akaza H; Deguchi T; Fujisawa M; Hayashi M; Hirao Y; Kanetake H; Naito S; Namiki M; Tachibana M; Usami M; Ohashi Y
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1385-96. PubMed ID: 18491137
[TBL] [Abstract][Full Text] [Related]
20. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
